Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Frequently asked questions
What sector does Kiniksa Pharmaceuticals Ltd (KNSA) operate in?
Kiniksa Pharmaceuticals Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Kiniksa Pharmaceuticals Ltd (KNSA) current stock price?
As of the latest data, Kiniksa Pharmaceuticals Ltd stock price is $78.67, with a previous close of $77.62. Kiniksa Pharmaceuticals Ltd gained $1.05 in the last trading session, representing a 1.35% increase.
What is Kiniksa Pharmaceuticals Ltd (KNSA) current market capitalization?
Kiniksa Pharmaceuticals Ltd market cap is approximately 3.80 billion.
What is Kiniksa Pharmaceuticals Ltd (KNSA) Earnings Per Share (EPS)?
The trailing EPS is $0.99, and the forward EPS is $1.62.
What is Kiniksa Pharmaceuticals Ltd (KNSA) Price-to-Earnings (P/E) ratio?
Kiniksa Pharmaceuticals Ltd current P/E ratio is 79.46, with a forward P/E of 48.63.
What is Kiniksa Pharmaceuticals Ltd (KNSA) EBITDA?
Kiniksa Pharmaceuticals Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 27.67 million.
Does Kiniksa Pharmaceuticals Ltd (KNSA) pay dividends?
No. Kiniksa Pharmaceuticals Ltd does not pay a dividend.
How did Kiniksa Pharmaceuticals Ltd (KNSA) perform in its most recent earnings report?
In the last report (June 30, 2026), Kiniksa Pharmaceuticals Ltd posted an EPS surprise of 0% and a revenue surprise of 7.57%.
When is Kiniksa Pharmaceuticals Ltd (KNSA) next earnings report?
Kiniksa Pharmaceuticals Ltd is expected to release its next earnings report on September 30, 2026.
What is Kiniksa Pharmaceuticals Ltd (KNSA) beta (volatility) score?
Kiniksa Pharmaceuticals Ltd has a beta of 0.085, indicating lower volatility than the overall market.
